# Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

> **NCT01260103** · PHASE3 · WITHDRAWN · sponsor: **Burzynski Research Institute**

## Conditions studied

- Optic Nerve Glioma

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** ANP Therapy

## Key facts

- **NCT ID:** NCT01260103
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-12
- **Primary completion:** 2016-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn: study halted prematurely, prior to enrollment of first participant
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260103, "Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01260103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*